Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

Acquisition of Babich-founded Noria helps Bayer pad radiopharmaceutical pipeline  

June 4, 2021 1:24 AM UTC

A deal unveiled Thursday will help Bayer expand its footprint in alpha-emitting targeted radiopharmaceuticals.

Bayer AG (Xetra:BAYN) announced it will acquire Noria Therapeutics Inc. and its subsidiary PSMA Therapeutics Inc., which have exclusive worldwide rights to targeted radiotherapy and diagnostic technology licensed from Weill Cornell Medicine and Johns Hopkins University, including an actinium 225-labeled, PSMA-targeting small molecule in preclinical development for prostate cancer. Financial details were not disclosed...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Bayer AG

Noria Therapeutics Inc.